

Appl. No. : 09/991,433
Filed : November 16, 2001

claims as originally filed and throughout the specification (e.g., page 12, lines 21-31; page 30, lines 22-26; page 31, lines 17-31; page 32, lines 1-4; and page 49, lines 1-10).

Applicants note that Claims 1, 4, 7, 8, 18, 21, 24, 25, and 35-43 are linked to and read-on the subject matter of Group I, Fragment (a), Species (1), *i.e.*, directed to capsid agents consisting of the sequence of glutamine-glutamine-tyrosine. Applicants also note that Claims 2, 3, 6, 19, 20, and 23 are linked to Group I and Fragment (a). Accordingly, Applicants respectfully request that upon a finding of patentability of claims directed to Species (1), a further examination of the patentability of the linking claims is undertaken.


The undersigned has made a good faith effort to respond to the Requirement for Restriction and top place the application in condition for immediate allowance. Nevertheless, if any undeveloped issues remain or if any issues require clarification, the Examiner is respectfully requested to call Applicants' attorney, Eric S. Furman, at (619) 687-8643 (direct line), to resolve such issues promptly.

This Response to Restriction Requirement has been filed with a one-month extension fee. No further fees are seen as being necessary. The Commissioner is authorized, however, to charge any fees in connection with this paper to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 11/27/02

By: 
Eric S. Furman, Ph.D.
Registration No. 45,664
Attorney of Record
Customer No. 20,995
(619) 235-8550

S:\DOCS\SRG\SRG-1126.DOC
112402
S:\DOCS\ESF\ESF-5944.DOC
112502